1. Home
  2. AXSM vs AB Comparison

AXSM vs AB Comparison

Compare AXSM & AB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AXSM
  • AB
  • Stock Information
  • Founded
  • AXSM 2012
  • AB 1987
  • Country
  • AXSM United States
  • AB United States
  • Employees
  • AXSM N/A
  • AB N/A
  • Industry
  • AXSM Biotechnology: Pharmaceutical Preparations
  • AB Investment Managers
  • Sector
  • AXSM Health Care
  • AB Finance
  • Exchange
  • AXSM Nasdaq
  • AB Nasdaq
  • Market Cap
  • AXSM 4.4B
  • AB 4.0B
  • IPO Year
  • AXSM 2015
  • AB 1988
  • Fundamental
  • Price
  • AXSM $95.84
  • AB $34.96
  • Analyst Decision
  • AXSM Strong Buy
  • AB Strong Buy
  • Analyst Count
  • AXSM 14
  • AB 5
  • Target Price
  • AXSM $124.57
  • AB $39.95
  • AVG Volume (30 Days)
  • AXSM 405.5K
  • AB 197.8K
  • Earning Date
  • AXSM 11-04-2024
  • AB 10-24-2024
  • Dividend Yield
  • AXSM N/A
  • AB 8.14%
  • EPS Growth
  • AXSM N/A
  • AB 26.36
  • EPS
  • AXSM N/A
  • AB 2.88
  • Revenue
  • AXSM $291,489,000.00
  • AB N/A
  • Revenue This Year
  • AXSM $42.50
  • AB N/A
  • Revenue Next Year
  • AXSM $69.28
  • AB $6.99
  • P/E Ratio
  • AXSM N/A
  • AB $12.13
  • Revenue Growth
  • AXSM 59.73
  • AB N/A
  • 52 Week Low
  • AXSM $55.02
  • AB $25.83
  • 52 Week High
  • AXSM $98.40
  • AB $35.67
  • Technical
  • Relative Strength Index (RSI)
  • AXSM 64.19
  • AB 59.70
  • Support Level
  • AXSM $89.24
  • AB $34.33
  • Resistance Level
  • AXSM $96.71
  • AB $35.30
  • Average True Range (ATR)
  • AXSM 3.66
  • AB 0.58
  • MACD
  • AXSM 0.02
  • AB 0.12
  • Stochastic Oscillator
  • AXSM 87.05
  • AB 85.65

About AXSM Axsome Therapeutics Inc.

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

About AB AllianceBernstein Holding L.P.

AllianceBernstein provides investment management services to institutional (42% of assets under management), retail (41%), and private (17%) clients through products that includes mutual funds, hedge funds, and separately managed accounts. At the end of July 2024, AB had $777 billion in managed assets, composed primarily of fixed-income (37% of AUM) and equity (43%) strategies, with other investments (made up of asset allocation services and certain other alternative investments) accounting for the remainder.

Share on Social Networks: